Edition:
United States

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

11.35USD
24 Mar 2017
Change (% chg)

$0.20 (+1.79%)
Prev Close
$11.15
Open
$11.35
Day's High
$11.45
Day's Low
$11.25
Volume
6,581
Avg. Vol
6,774
52-wk High
$20.98
52-wk Low
$10.35

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
Tuesday, 14 Mar 2017 06:00am EDT 

Cellular Biomedicine Group Inc : Cellular biomedicine group reports full-year 2016 financial results and recent operational progress .Cellular biomedicine group inc- had working capital of $38.3 million as of december 31, 2016 compared to $13.7 million as of december 31, 2015.  Full Article

Cellular Biomedicine Group announces resale of up to 5.1 mln shares of common stock for sale by selling stockholders
Monday, 20 Jun 2016 05:25pm EDT 

Cellular Biomedicine Group Inc :Resale of up to 5.1 million shares of common stock for sale by the selling stockholders - SEC filing.  Full Article

Cellular Biomedicine reports Q1 results
Monday, 9 May 2016 04:01pm EDT 

Cellular Biomedicine Group Inc : Cellular Biomedicine Group Inc says cash and cash equivalents as of march 31, 2016 were $15.7 million compared to $14.9 million as of december 31, 2015 . Cellular biomedicine group reports first quarter 2016 financial results and provides business highlights .Q1 revenue $488,500 versus $603,400.  Full Article

Cellular Biomedicine Group Inc announces positive 48-week data from phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy
Wednesday, 13 Jan 2016 08:00am EST 

Cellular Biomedicine Group Inc:Announces positive 48-week data from phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy.Says no serious adverse events reported to date.Says 48-week end of study shows primary,secondary endpoints of rejoin therapy group having improved significantly compared to baseline.Says total womac scores as a primary end point show statistical treatment significance at week 48 compared to the baseline.  Full Article

Cellular Biomedicine Group Inc says Wei Cao will not seek renewal of employment contract as CEO
Monday, 11 Jan 2016 09:01am EST 

Cellular Biomedicine Group Inc:Says Wei Cao will not seek renewal of employment contract as CEO.Says committee of board has been established to oversee the professional recruitment of a new chief executive officer.Tony Liu, will assume full responsibilities as the interim chief executive officer.  Full Article

Cellular Biomedicine Group Inc announces entry into material definitive agreement - Form 8-K
Thursday, 2 Jul 2015 03:08pm EDT 

Cellular Biomedicine Group Inc:Says on June 12, on June 8, Cellular Biomedicine Group Inc and its wholly-owned subsidiary, Cellular Biomedicine Group Vax, Inc., signed an asset purchase agreement with Blackbird BioFinance, LLC (Blackbird) and certain of its principals.To acquire certain license rights to technology and know-how from Blackbird (purchased assets) and assume certain post-closing liabilities relating to Purchased Assets for a total cash and equity consideration of $4,250,000.Prior to closing, Blackbird held an exclusive worldwide license to CD40LGVAX vaccine from University of South Florida (USF), which granted exclusive rights to certain know-how, clinical work, manufacturing procedures, and derivative products related to vaccine.  Full Article

Cellular Biomedicine Group Inc completes acquisition of CD40LGVAX Vaccine
Monday, 29 Jun 2015 09:00am EDT 

Cellular Biomedicine Group Inc:Has completed previously said acquisition of Blackbird Bio Finance and University of South Florida's (Licensor) next generation GVAX vaccine's (CD40LGVAX) related technologies and technical knowledge.With close of this acquisition, management believes that the Company will be able to offer comprehensive immuno-oncology cell therapy portfolios, as well as broad set of options for patients.Under terms of agreement, CBMG will pay an initial consideration of $2.5 mln in cash and up to $1.75 mln in shares of the Company's Common Stock, which is based on the 20-day volume, weighted average price ("VWAP") of the Company's Common Stock on the closing date of June 29.As licensee of CD40LGVAX, the Company could pay potentially more than $25M in future milestone and sales royalty payments to the Licensor.Additional information can be found in the Form 8-K filed by Cellular Biomedicine Group with the Securities and Exchange Commission on June 12.  Full Article

Cellular Biomedicine enters agreement to acquire cd40lgvax vaccine and related technologies
Tuesday, 9 Jun 2015 08:30am EDT 

Cellular Biomedicine:Enters into definitive agreement to acquire cd40lgvax vaccine and related technologies and know-how which will be used in a pending pd-1 combination clinical trial in the U.S. for non-small cell lung cancer (nsclc.Says initial consideration of $2.5 million in cash and $1.75 million in shares of the company's common stock.To acquire from blackbird bio finance university of south Florida's next generation gvax vaccine's related technologies.Says will pay potentially more than $25 million in future milestones and royalty payments.  Full Article

Cellular Biomedicine Group announces positive phase I results from CAR-T CD30 immuno-oncology clinical development program
Friday, 22 May 2015 09:17am EDT 

Cellular Biomedicine Group:Says encouraging clinical data from its Chimeric Antigen Receptor (CAR-T) CD30-positive Hodgkin's lymphoma immuno-oncology clinical development program.Says results of this trial to date demonstrated that five out of seven patients responded to the treatment.CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient.  Full Article

Cellular Biomedicine Group responds to purported class action lawsuit
Thursday, 30 Apr 2015 06:30pm EDT 

Cellular Biomedicine Group:Intends to vigorously defend against the claims made in a putative securities class action lawsuit filed against the company and two of its officers in the United States District Court for the Northern District of California.Complaint is based in large part on an anonymous article published on the Seeking Alpha website, which CBMG has already addressed on its website. CBMG has reviewed the complaint and views the allegations as meritless.Adrienne Marie Ward of Ellenoff Grossman & Schole LLP (EGS) will serve as lead defense counsel for CBMG and its officers.Barry Grossman of EGS will also advise the Company in connection with its defense of the class actions.  Full Article

More From Around the Web

BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31

* Cellular biomedicine group reports full-year 2016 financial results and recent operational progress